A new study demonstrates the design and potential of adding artificial components to bacteria to enable tumour targeted drug release and immune activation.
List view / Grid view
If the proof-of concept trial of AVA6000 Pro-doxorubicin is successful, it could lead to a pipeline of pro-drug chemotherapies with limited toxicity, say the drug's developers.
Co-injecting doxorubicin with LATTE, a novel ionic liquid formulation, resulted in uniform chemotherapy delivery and successful ablation in solid tumours.
Chemotherapy drugs commonly used in breast cancer leads to a decrease in muscle mitochondria, and could result in fatigue after treatment...
Doxorubicin induced irreversible dysregulation which decreased the levels of lipoxygenases and cyclooxygenases in the left ventricle...
Researchers have shown a method to functionalize liposomes for specific targeting, potentially paving the way for personalised medicine...
Olaratumab is the first monoclonal antibody, in combination with doxorubicin, to be recommended for the treatment of advanced soft tissue sarcoma.
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
This conditional marketing authorisation is based on data from the Phase 2 portion of the pivotal JGDG trial and followed a positive recommendation from...
21 July 2016 | By Niamh Louise Marriott, Digital Content Producer
Scientists discovered that adding a novel monoclonal antibody therapy to traditional chemotherapy increased survival by nearly a year in patients with advanced sarcoma, a lethal soft-tissue cancer.
4 May 2016 | By Victoria White, Digital Content Producer
The US Food and Drug Administration (FDA) has granted Priority Review to Lilly’s biologics license application (BLA) for olaratumab, in combination with doxorubicin, for the potential treatment of people with advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery.